Bulk Manufacturer of Controlled Substances Application: Noramco Coventry LLC, 70148 [2021-26676]
Download as PDF
<![CDATA[
70148
Federal Register / Vol. 86, No. 234 / Thursday, December 9, 2021 / Notices
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 10, 2022. Such
persons may also file a written request
for a hearing on the application on or
before January 10, 2022.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
In
accordance with 21 CFR 1301.34(a), this
is notice that on September 8, 2021,
Fresenius Kabi USA, LLC, 3159 Staley
Road, Grand Island, New York 14072–
2028, applied to be registered as an
importer of the following basic class of
controlled substance:
SUPPLEMENTARY INFORMATION:
Drug
code
Controlled substance
Remifentanil ...................
I
9739
Schedule
I II
The company plans to import the
listed controlled substances for bulk
manufacture. No other activity for this
drug code is authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Brian S. Besser,
Acting Assistant Administrator.
khammond on DSKJM1Z7X2PROD with NOTICES
[FR Doc. 2021–26677 Filed 12–8–21; 8:45 am]
Drug Enforcement Administration
[Docket No. DEA–928]
Bulk Manufacturer of Controlled
Substances Application: Noramco
Coventry LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
20:15 Dec 08, 2021
Jkt 256001
these drugs as synthetics. No other
activities for these drug codes are
authorized for this registration.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021–26676 Filed 12–8–21; 8:45 am]
BILLING CODE P
AGENCY:
NATIONAL SCIENCE FOUNDATION
Noramco Coventry LLC, has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplemental Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before February 7, 2022. Such
persons may also file a written request
for a hearing on the application on or
before February 7, 2022.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUMMARY:
In
accordance with 21 CFR 1301.33(a), this
is notice that on September 29, 2021,
Noramco Coventry LLC, 498
Washington Street, Coventry, Rhode
Island 02816, applied to be registered as
a bulk manufacturer of the following
basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug
code
Schedule
Notice of Permits Issued Under the
Antarctic Conservation Act of 1978
National Science Foundation.
Notice of permits issued.
AGENCY:
ACTION:
The National Science
Foundation (NSF) is required to publish
notice of permits issued under the
Antarctic Conservation Act of 1978.
This is the required notice.
FOR FURTHER INFORMATION CONTACT:
Polly Penhale, ACA Permit Officer,
Office of Polar Programs, National
Science Foundation, 2415 Eisenhower
Avenue, Alexandria, VA 22314; 703–
292–8030; email: ACApermits@nsf.gov.
SUPPLEMENTARY INFORMATION: On
November 5, 2021, the National Science
Foundation published a notice in the
Federal Register of permit applications
received. The permits were issued on
December 6, 2021, to:
1. Henry Wulff, Atlas Ocean
Voyages—Permit No. 2022–021
2. Deirdre Dirkman, Vantage Deluxe
World Travel—Permit No. 2022–022
3. Tom Russell, Swan Hellenic
Antarctic—Permit No. 2022–023
4. Michael Hjorth, Albatros
Expeditions—Permit No. 2022–024
SUMMARY:
Erika N. Davis,
Program Specialist, Office of Polar Programs.
[FR Doc. 2021–26671 Filed 12–8–21; 8:45 am]
Marihuana ......................
Tetrahydrocannabinols ..
Dihydromorphine ...........
Methylphenidate ............
Oxycodone ....................
Hydromorphone .............
Hydrocodone .................
Levorphanol ...................
Morphine ........................
Oripavine .......................
Thebaine ........................
Oxymorphone ................
Noroxymorphone ...........
Tapentadol .....................
7360
7370
9145
1724
9143
9150
9193
9220
9300
9330
9333
9652
9668
9780
I
I
I
II
II
II
II
II
II
II
II
II
II
II
The company plans to bulk
manufacture the listed controlled
substances for use as intermediates and
converted to other controlled substances
or for sale to its customers. In reference
to drug codes 7360 (Marihuana), and
7370 (Tetrahydrocannabinols), the
company plans to bulk manufacture
BILLING CODE P
VerDate Sep<11>2014
DEPARTMENT OF JUSTICE
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
BILLING CODE 7555–01–P
NATIONAL SCIENCE FOUNDATION
Notice of Permits Issued Under the
Antarctic Conservation Act of 1978
National Science Foundation.
Notice of permit issued.
AGENCY:
ACTION:
The National Science
Foundation (NSF) is required to publish
notice of permits issued under the
Antarctic Conservation Act of 1978.
This is the required notice.
FOR FURTHER INFORMATION CONTACT:
Polly Penhale, ACA Permit Officer,
Office of Polar Programs, National
Science Foundation, 2415 Eisenhower
Avenue, Alexandria, VA 22314; 703–
292–8030; email: ACApermits@nsf.gov.
SUMMARY:
E:\FR\FM\09DEN1.SGM
09DEN1
]]>Agencies
[Federal Register Volume 86, Number 234 (Thursday, December 9, 2021)]
[Notices]
[Page 70148]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-26676]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-928]
Bulk Manufacturer of Controlled Substances Application: Noramco
Coventry LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Noramco Coventry LLC, has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before February 7,
2022. Such persons may also file a written request for a hearing on the
application on or before February 7, 2022.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on September 29, 2021, Noramco Coventry LLC, 498
Washington Street, Coventry, Rhode Island 02816, applied to be
registered as a bulk manufacturer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Marihuana.............................. 7360 I
Tetrahydrocannabinols.................. 7370 I
Dihydromorphine........................ 9145 I
Methylphenidate........................ 1724 II
Oxycodone.............................. 9143 II
Hydromorphone.......................... 9150 II
Hydrocodone............................ 9193 II
Levorphanol............................ 9220 II
Morphine............................... 9300 II
Oripavine.............................. 9330 II
Thebaine............................... 9333 II
Oxymorphone............................ 9652 II
Noroxymorphone......................... 9668 II
Tapentadol............................. 9780 II
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances for use as intermediates and converted to other controlled
substances or for sale to its customers. In reference to drug codes
7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans
to bulk manufacture these drugs as synthetics. No other activities for
these drug codes are authorized for this registration.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021-26676 Filed 12-8-21; 8:45 am]
BILLING CODE P
